30 January 2024: TechBio company, Cytomos (www.cytomos.com) is pleased to announce that Dr Fernanda Masri, the company’s Chief Commercial and Innovation Officer, and former Head of Innovation Manufacturing and Collaborations at Cell and Gene Therapy Catapult, will co-chair the 2024 Biannual ECI Advancing Manufacture of Cell and Gene Therapies conference, taking place between 4th and 8th February 2024 in Coronado, California. Moreover, Fernanda will co-chair the meeting’s fireside chat opening session – providing an overview of the expectations now placed on the cell and gene therapy manufacturing industry that go far beyond good science and clinical impact.
The conference brings together an international array of figures from academia, industry and government, to showcase and debate the latest breakthroughs in advancing and improving the engineering and manufacturing of advanced, next generation therapies. Conference sessions cover enabling technologies that have been developed to overcome many of the limitations of current processes, potentially including obstacles and challenges that prevent automation, a key goal in the production process for these therapies. “Over the course of the next 5-10 years, next generation process analytical enabling technologies have huge potential to serve as key drivers for accelerating new product discovery, development and manufacturing. They hold the key to unlocking the true long-term potential of cell and gene therapies because of their capability to radically decrease the cost of producing the products, whilst increasing their robustness and
reliability,” commented Dr Masri. For example, technological innovations – like Cytomos’s AuraCyt™ platform – accelerate biological drug discovery and development, streamline manufacturing, with real-time monitoring potential, and provide better prospects for delivering automation in the future production of cell and gene therapies.
CEO David Rigterink added, “We are delighted that Cytomos is associated with this excellent conference through Fernanda’s involvement in its organisation and implementation. It reflects our company’s focus on delivering novel solutions for unbiased, consistent, accurate and reliable predictive analytics for biomanufacturing and other applications. Cytomos has been building on the past decade’s profound DeepTech R&D progress, and the expected CE approval for our brand-new benchtop instrument, Celledonia™ – which will allow a market launch in Q2 – marks the start of a seismic disruption to the single cell analytical market.”
To download a copy of the original press release click here.
30 January 2024
[gravityform id="1" title="false"]